331 related articles for article (PubMed ID: 23907751)
1. Everolimus: side effect profile and management of toxicities in breast cancer.
Paplomata E; Zelnak A; O'Regan R
Breast Cancer Res Treat; 2013 Aug; 140(3):453-62. PubMed ID: 23907751
[TBL] [Abstract][Full Text] [Related]
2. Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer.
Peddi PF; Shatsky RA; Hurvitz SA
Cancer Treat Rev; 2014 Mar; 40(2):320-6. PubMed ID: 24011786
[TBL] [Abstract][Full Text] [Related]
3. Everolimus in the treatment of hormone receptor-positive breast cancer.
Chavez-MacGregor M; Gonzalez-Angulo AM
Expert Opin Investig Drugs; 2012 Dec; 21(12):1835-43. PubMed ID: 22994502
[TBL] [Abstract][Full Text] [Related]
4. Adverse event management of mTOR inhibitors during treatment of hormone receptor-positive advanced breast cancer: considerations for oncologists.
Yardley DA
Clin Breast Cancer; 2014 Oct; 14(5):297-308. PubMed ID: 25065566
[TBL] [Abstract][Full Text] [Related]
5. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial.
Peterson ME
Support Care Cancer; 2013 Aug; 21(8):2341-9. PubMed ID: 23686401
[TBL] [Abstract][Full Text] [Related]
6. Everolimus: a new hope for patients with breast cancer.
Sendur MA; Zengin N; Aksoy S; Altundag K
Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin: biological function and target for novel anticancer agents.
Borders EB; Bivona C; Medina PJ
Am J Health Syst Pharm; 2010 Dec; 67(24):2095-106. PubMed ID: 21116000
[TBL] [Abstract][Full Text] [Related]
8. Everolimus: targeted therapy on the horizon for the treatment of breast cancer.
Barnett CM
Pharmacotherapy; 2012 Apr; 32(4):383-96. PubMed ID: 22461124
[TBL] [Abstract][Full Text] [Related]
9. Practical management of everolimus-related toxicities in patients with advanced solid tumors.
Grünwald V; Weikert S; Pavel ME; Hörsch D; Lüftner D; Janni W; Geberth M; Weber MM
Onkologie; 2013; 36(5):295-302. PubMed ID: 23689226
[TBL] [Abstract][Full Text] [Related]
10. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus.
Hadji P; Coleman R; Gnant M
Crit Rev Oncol Hematol; 2013 Aug; 87(2):101-11. PubMed ID: 23838481
[TBL] [Abstract][Full Text] [Related]
11. Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer.
Ng VC; Johnson JJ; Cuellar S
J Oncol Pharm Pract; 2015 Dec; 21(6):433-42. PubMed ID: 24964967
[TBL] [Abstract][Full Text] [Related]
12. [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
Gilabert M; Launay S; Gonçalves A
Bull Cancer; 2014 Mar; 101(3):325-33. PubMed ID: 24691195
[TBL] [Abstract][Full Text] [Related]
13. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.
Rugo HS; Pritchard KI; Gnant M; Noguchi S; Piccart M; Hortobagyi G; Baselga J; Perez A; Geberth M; Csoszi T; Chouinard E; Srimuninnimit V; Puttawibul P; Eakle J; Feng W; Bauly H; El-Hashimy M; Taran T; Burris HA
Ann Oncol; 2014 Apr; 25(4):808-815. PubMed ID: 24615500
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-15 gene therapy and the mammalian target of rapamycin inhibitor everolimus inhibit the growth of metastatic breast cancer.
Zhao N; Li X; He X; Qiu Y; Zhu L; Qi F
J Gene Med; 2013 Oct; 15(10):366-74. PubMed ID: 24038990
[TBL] [Abstract][Full Text] [Related]
15. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
Thompson LA; Kim M; Wenger SD; O'Bryant CL
Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
[TBL] [Abstract][Full Text] [Related]
16. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
Rugo HS; Seneviratne L; Beck JT; Glaspy JA; Peguero JA; Pluard TJ; Dhillon N; Hwang LC; Nangia C; Mayer IA; Meiller TF; Chambers MS; Sweetman RW; Sabo JR; Litton JK
Lancet Oncol; 2017 May; 18(5):654-662. PubMed ID: 28314691
[TBL] [Abstract][Full Text] [Related]
17. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.
Lo Muzio L; Arena C; Troiano G; Villa A
Oral Dis; 2018 Mar; 24(1-2):144-171. PubMed ID: 29480626
[TBL] [Abstract][Full Text] [Related]
18. [Combination of exemestane and everolimus may produce toxic side effects: a new treatment option for metastatic hormone-sensitive breast cancer].
Vincent J; de Boer M; Lobbezoo DJ; Smeets RE; Tjan-Heijnen VC
Ned Tijdschr Geneeskd; 2014; 158():A7523. PubMed ID: 25115205
[TBL] [Abstract][Full Text] [Related]
19. [Hyperglycaemia during treatment with everolimus].
Opdam FL; Huitema AD; Beijnen JH; Schellens JH
Ned Tijdschr Geneeskd; 2014; 158():A7544. PubMed ID: 25115206
[TBL] [Abstract][Full Text] [Related]
20. Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management.
Nicolatou-Galitis O; Nikolaidi A; Athanassiadis I; Papadopoulou E; Sonis S
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Aug; 116(2):e110-6. PubMed ID: 23643584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
